CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Children's Hospital of Philadelphia · Pediatrics and Genetics · +1 more institution
Abstract
Relapsed and refractory acute lymphoblastic leukemia (ALL) remains difficult to treat, with minimal improvement in outcomes seen in more than 2 decades despite advances in upfront therapy and improved survival for de novo ALL. Adoptive transfer of T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory populations. Complete remission (CR) rates as high as 90% have been reported in children and adults with relapsed and refractory ALL treated with CAR-modified T cells targeting the B-cell-specific antigen CD19. Distinct CAR designs across several studies have produced similar promising CR rates, an…
Citation impact
- FWCI
- 37.95
- Percentile
- 100%
- References
- 80
Authors
4Topics & keywords
- Chimeric antigen receptor
- Cytokine release syndrome
- CD19
- Immunology
- Medicine
- Immunotherapy
- Cell therapy
- Blinatumomab
Funding
- AAAmerican Association for Cancer ResearchAward: SU2C-AACR-DT1113
- ACAmerican Cancer Society
- PDPennsylvania Department of Health
- LALeukemia and Lymphoma Society
- EIEntertainment Industry Foundation
- NINational Institutes of HealthAwards: R01CA116660, R01CA102646
- SUStand Up To CancerAward: SU2C-AACR-DT1113
- NCNational Cancer Institute